UK Health Chief: High Drug Prices Fatten Pharma Execs’ Paychecks

The UK body that decides which drugs are cost-effective is often attacked when it decides new treatments that offer only small benefits aren’t worth a high price. But in an interview published in the Observer this weekend, Sir Michael Rawlins, the chairman of the National Institute for Health and Clinical Excellence (NICE), comes out swinging.